Valneva is hosting an Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET.

Saint-Herblain (France), October 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccines company, today announced that it will host an investor day at the Lotte New York Palace Hotel in New York, New York on Thursday, October 10, 2024 at 10:00 a.m. ET ( 4:00 PM CET).

The meeting will be held in a hybrid manner – in person and webcast. To register, Click here.

The event will focus on Valneva's strong R&D pipeline for first-, single-, or best-in-class vaccine candidates to address key unmet medical needs in infectious diseases: Lyme disease (Phase 3, led by Pfizer), Shigella (Phase 2) and Zika (Phase 1). ). It will also highlight Valneva's growing portfolio of revenue-generating vaccines, including the launch of the world's first and only approved vaccine against the chikungunya virus.

Speakers from the company's management include Thomas Lengelbach, CEO and member of the Board of Directors, as well as other members of the management team.

A live Q&A session will follow the formal presentation.

About Valneva SE
We are a specialty vaccine company that develops, manufactures and markets preventive vaccines for infectious diseases to address unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, with a focus on providing first, best or only vaccine solutions in class.

We have a proven track record, having developed multiple vaccines from early R&D through approvals, and currently commercialize three of our own travel vaccines, including the world's first and only chikungunya vaccine, as well as certain third-party vaccines.

Revenues from our growing commercial business help fuel the continued progress of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, in partnership with Pfizer, the world's most clinically advanced shigella vaccine candidate, as well as vaccine candidates against Zika virus and other global public health threats. More information is available at www.valneva.com.

Forward-looking statements
This press release contains certain forward-looking statements relating to Valneva's business, including with respect to the progress, timing, results and completion of research, development and clinical trials of product candidates, regulatory approval of product candidates and review of existing products. . In addition, even if actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, such results or development of Valneva may not continue in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “would,” “expects,” “anticipates,” “believes,” “intends,” and “estimates.” , “aims”, “objectives” or similar words. These forward-looking statements are based largely on Valneva's current expectations as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and other factors that could cause them to materially affect actual results, performance or achievements. differs from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, Valneva's forecasts could be affected by, among other things, uncertainties and delays in the development and manufacturing of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition generally, currency fluctuations, the impact of the global and European credit crisis, capacity To obtain or maintain patents or other intellectual property protection. Success in preclinical studies or previous clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this press release will actually materialize. Valneva provides this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.